

26 February 2026

Botanix Webinar – 3 March – Registration Information

Philadelphia PA and Phoenix AZ, 26 February 2026: Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), announces that registration is open for an investor webinar hosted by Executive Chairman Vince Ippolito, Chief Executive Officer Dr Howie McKibbin and US Chief Financial Officer Chris Lesovitz. The webinar will share comprehensive insights into the Company’s Half Year Financial Report.

The webinar will be held on Tuesday, 3 March 2026, at 11 am AEDT (Sydney/ Melbourne)/8 am AWST (Perth). Interested participants **must register before the webinar using the link below**. Dial-in details will be sent in return.

Webinar Details

Date: 3 March 2026

Time: 11 am AEDT (Sydney/Melbourne), 8 am AWST (Perth)

To register: https://us06web.zoom.us/webinar/register/WN_8BQalV5cRuaR5_c-S5Dh_g

Dial-in details: Will be sent to you directly upon registration

Release authorised by

Vince Ippolito

Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

P: +61 4 5064 8064

investors@botanixpharma.com

Media enquiries

Haley Chartres

HACK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra*[®] and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.